Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Epizyme, Inc. (EPZM)

1.47   0 (0%) 09-24 16:35
Open: 1.49 Pre. Close: 1.47
High: 1.4993 Low: 1.47
Volume: 0 Market Cap: 247(M)
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.5 - 1.51 1.51 - 1.52
Low: 1.45 - 1.46 1.46 - 1.47
Close: 1.46 - 1.47 1.47 - 1.48

Technical analysis

as of: 2022-09-23 4:23:49 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.73     One year: 1.75
Support: Support1: 1.47    Support2: 1.22
Resistance: Resistance1: 1.48    Resistance2: 1.49
Pivot: 1.47
Moving Average: MA(5): 1.47     MA(20): 1.47
MA(100): 1.15     MA(250): 1.94
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 0     %D(3): 0
RSI: RSI(14): 60.7
52-week: High: 5.23  Low: 0.41
Average Vol(K): 3-Month: 1,549 (K)  10-Days: 0 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EPZM ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 49 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 12 Aug 2022
Epizyme Inc. (EPZM) expanding its growth trajectory ahead - SETE News

Fri, 05 Aug 2022
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022 - Ipsen

Tue, 26 Jul 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, EPZM, LION - PR Newswire

Mon, 25 Jul 2022
SHAREHOLDER ALERT: Weiss Law Reminds WWE, DRE, MN, and EPZM Shareholders About Its Ongoing Investigations - PR Newswire

Mon, 18 Jul 2022
Should You Buy Epizyme Inc (EPZM) Stock on Monday? - InvestorsObserver

Sat, 16 Jul 2022
Shareholder Alert - The M&A Class Action Firm Continues Investigating the Merger - FSTX, EPZM, STCN, SIMO, VMW, VHAQ - PR Newswire

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 168 (M)
Shares Float 135 (M)
% Held by Insiders 0.5 (%)
% Held by Institutions 81 (%)
Shares Short 2,340 (K)
Shares Short P.Month 4,740 (K)

Stock Financials

EPS -2.09
EPS Est Next Qtl -0.68
EPS Est This Year -2.36
EPS Est Next Year -2.45
Book Value (p.s.) -0.12
Profit Margin (%) 0
Operating Margin (%) -365.4
Return on Assets (ttm) -39.3
Return on Equity (ttm) -877.5
Qtrly Rev. Growth 111.5
Gross Profit (p.s.) 0.11
Sales Per Share 0.31
EBITDA (p.s.) -1.12
Qtrly Earnings Growth 0
Operating Cash Flow -209 (M)
Levered Free Cash Flow -128 (M)

Stock Valuations

PE Ratio -0.71
PEG Ratio -0.1
Price to Book value -12.26
Price to Sales 4.66
Price to Cash Flow -1.19

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.